Screening for Cognitive Impairment Associated with Chemotherapy for Breast Cancer
At least 20 % of women treated with chemotherapy for breast cancer experience some form of cognitive decline. Recent recommendations call for clinicians to screen cognitive abilities. Screening of factors that can contribute to cognitive impairment is also currently recommended. We describe a battery of free, online, self-report surveys that would take approximately 30 min to complete in the context of an overall functional assessment of wellness. Key physical characteristics to be screened include fatigue and insomnia. Significant psychological characteristics include distress, depression, and anxiety. Fundamental social characteristics include basic needs, workplace issues, and interpersonal well-being. Systematic screening that could be completed in the clinic waiting room or during chemotherapy infusion is an important first step towards more holistic patient care that addresses cognitive side effects, just as physical side effects of treatment are routinely addressed.
KeywordsBreast neoplasms Adjuvant chemotherapy Adverse effects Brain Cognition Cognition disorders Memory Executive function Fatigue Psychological stress Depression Anxiety Surveys and questionnaires Survivors Quality of life
The study was supported by an Advanced Rehabilitation Research Training Award: Interventions for Neurologic Communication Disorders (award no. 90AR5015-01-00) from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) and the Evergreen Invitational Women’s Health Grants Initiative. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Compliance with Ethical Standards
Conflict of Interest
Diane F. Morean and Leora R. Cherney declare that they have nothing to declare.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.World Health Organization. Cancer: fact sheet 297. 2015. Retrieved from http://www.who.int/mediacentre/factsheets/fs297/en/Google Scholar
- 2.American Cancer Society. Global cancer facts and figures, 2nd edition. 2008. Retrieved from http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf
- 17.Hendren S, Chin N, Fisher S, Winters P, Griggs J, Mohile S, et al. Patients’ barriers to receipt of cancer care, and factors associated with needing more assistance from a patient navigator. J Natl Med Assoc. 2011;103:701–10. doi: 10.1016/S0027-9684(15)30409-0.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.•Wagner LI, Spiegel D, Pearman T. Using the science of psychosocial care to implement the new American College of Surgeons commission on cancer distress screening standard. J Natl Compr Cancer Netw. 2013;1:214–21. This focused review provides practical information on implementing screening standards into routine breast cancer treatment. Google Scholar
- 23.de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, Caan M, Douaud G, et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp. 2012;33:2971–83. doi: 10.1002/hbm.21422.CrossRefPubMedGoogle Scholar
- 24.Deprez S, Amant F, Smeets A, Peeters R, Leemans A, Van Hecke W, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30:274–81. doi: 10.1200/JCO.2011.36.8571.CrossRefPubMedGoogle Scholar
- 25.Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat. 2007;103:303–11. doi: 10.1007/s10549-006-9380-z.CrossRefPubMedGoogle Scholar
- 26.••Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. J Clin Oncol. 2016;34:611–35. doi: 10.1200/JCO.2015.64.3809. This ASCO special article provides recommendations to assist primary care and other clinicians in the care of breast cancer survivors, including assessment and management of cognitive impairment and contributing factors of cognitive impairment. CrossRefPubMedGoogle Scholar
- 27.••American College of Surgeons Commission on Cancer (2016). Cancer program standards: ensuring patient-centered care manual, 2016 edition. Retrieved from https://www.facs.org/~/media/files/quality%20programs/cancer/coc/2016%20coc%20standards%20manual_interactive%20pdf.ashx. This manual describes CoC accreditation requirements including psychosocial distress screening and navigation.
- 29.Wagner L, Sweet J, Butt Z, Lai J, Cella D. Measuring patient self-reported cognitive function: development of the Functional Assessment of Cancer Therapy–Cognitive Function instrument. J Support Oncol. 2009;7:W32–9.Google Scholar
- 31.López Zunini RA, Scherling C, Wallis N, Collins B, MacKenzie J, Bielaiew C, et al. Differences in verbal memory retrieval in breast cancer chemotherapy patients compared to healthy controls: a prospective fMRI study. Brain Imaging Behav. 2013;7:460–77. doi: 10.1007/s11682-012-9213-0.CrossRefPubMedGoogle Scholar
- 34.Downie FP, Mar Fan HG, Houédé-Tchen N, Yi Q, Tannock IF. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psychooncology. 2006;15:921–30. doi: 10.1002/pon.1035.CrossRefPubMedGoogle Scholar
- 38.Lyon DE, Cohen R, Chen H, Kelly DL, Starkweather A, Ahn H et al. The relationship of cognitive performance to concurrent symptoms, cancer- and cancer-treatment-related variables in women with early-stage breast cancer: a 2-year longitudinal study. J Cancer Res Clin Oncol. 2016, 1-14. doi: 10.1007/s00432-016-2163-y
- 47.National Heart Lung and Blood Institute. What causes anemia? 2012. Retrieved from http://www.nhlbi.nih.gov/health/health-topics/topics/anemia/causes
- 54.Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12:160–74. doi: 10.1016/S1470-2045(11)70002-X.CrossRefPubMedGoogle Scholar
- 55.Lovibond SH, Lovibond PF. Manual for the depression anxiety stress scales. 2nd ed. Sydney: Psychology Foundation; 1995.Google Scholar
- 56.Bauer A. Cancer.net, Spotlight on: oncology social workers–Part I, a Q&A. 2014. Retrieved from http://www.cancer.net/blog/2014-04/spotlight-oncology-social-workers-%E2%80%93-part-i-qa
- 57.Web Finance Inc. Work environment. 2014. Retrieved from http://www.businessdictionary.com/definition/work-environment.html